A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Markus Borner(University of Bern), A. Roth(University Hospital of Zurich), Martin Wernli(Kantonsspital Aarau), Damien Dietrich(University Hospital of Bern), Piercarlo Saletti(Institute of Oncology Research), Doris Lanz(Queen Mary University of London), Peter Brauchli(University of St.Gallen), Dieter Koeberle(Kantonsspital St. Gallen), Răzvan Popescu(Hirslanden Klinik Aarau), Richard Herrmann(New York State Department of Health), Hanspeter Honegger(University Hospital of Bern), J. Bernhard(International Breast Cancer Study Group), Daniel Rauch(Washington University in St. Louis)
Cited by 103
Related Papers
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
|JNCI Journal of the National Cancer Institute|2012|279
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
|Annals of Oncology|2019|244